NextCure Inc
nextcure.comWhat Do They Do?
Develops targeted cancer drug candidates, including antibody-drug conjugates, for patients whose cancers do not respond to or progress on current therapies.
10-K for FY2025, filed Mar 5, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 6, 2026
−$14.9MView ↗
- ▼ −44% (Loss)
- vs −$26.8M in Q2 FY2025
-
Aug 6, 2026
Announces proposed merger with Avere Therapeutics
The all-stock deal would make the combined company Avere Therapeutics, subject to stockholder approval and other closing conditions.
Sources
8-K, filed Aug 6, 2026
Announced a definitive merger agreement with Avere Therapeutics in an all-stock transaction. Upon closing, the combined company is expected…View ↗
Therapy focus
The older report describes discovering immunomedicines through its FIND-IO platform and advancing immune-based candidates; the latest report centers on antibody-drug conjugates and seeks partners for other clinical programs.
10-K for FY2022, filed Mar 2, 2023 10-K for FY2025, filed Mar 5, 2026We are a clinical-stage biopharmaceutical company that is focused on advancing innovative medicines that treat cancer patients that do not…View ↗
We are uniquely positioned in the ADC field, with ADCs targeting two clinically validated targets, leveraging two distinct payloads: a…View ↗
In addition, we are seeking to partner our other clinical programs NC410 and NC525 and to pursue a partner or obtain third-party financing…View ↗
Who Do They Compete With?
Competes with Merck &, Daiichi Sankyo, OnCusp Therapeutics, Hansoh Pharma, AbbVie, Genmab, AstraZeneca, BeiGene, GSK, and Day One Biopharmaceuticals
10-K for FY2025, filed Mar 5, 2026SIM0505 faces a competitive landscape of CDH6-targeted programs in clinical development, most notably raludotatug deruxtecan (R-DXd), a…View ↗
Loading...
